This work was supported by the Wilmot Cancer Institute Predoctoral Fellowship (G.A.), Wilmot Cancer Institute Pilot Funding (I.S.H.), the American Association for Cancer Research and Breast Cancer Research Foundation (20-20-26-HARR) (I.S.H.), Breast Cancer Coalition of Rochester (I.S.H.), a Sir Henry Wellcome Postdoctoral Fellowship (M.E.K.), and a FNR-CORE grant C21/BM/15796788 (D.B.), and NIH grants R01CA269813 (I.S.H.), R37CA230042 (G.M.D), R24AA022057 (V.V.), R01AA028859 (Y.C.), AI150698 (J.M.), K01CA240533-01A1 (C.L.C.), and R01AR078000 (R.T.D.)
Consistent with these clinical trials, several recent studies have reported that DPP-4i can alleviate hypertensive conditions in animal models (1519)
1) Targets Fat Metabolism (AOD 9604) Supports pathways commonly associated with: fat breakdown stubborn fat reduction support lean tissue protection during dieting 2) Supports Energy + Metabolic Flexibility (MOTS-c) Supports: mitochondrial energy production better fuel utilization (carbs + fats) metabolic resilience during stress, dieting, or busy seasons 3) Supports Visceral Fat + Midsection Goals (Tesamorelin) Supports: visceral fat reduction in certain individuals midsection-focused body composition goals metabolic pathway support under provider guidance 4) Supports Recovery + Sleep (Ipamorelin) Supports: deeper, more restorative sleep better recovery between workouts improved consistency (because you feel better while leaning out) In simple terms: AOD + MOTS-c help the metabolism feel on, Tesamorelin supports midsection/visceral fat goals, and Ipamorelin helps you recover and sleep so you can stay consistent
Yet not one of them went through long-term trials to determine whether or not they would be safe for a lifetime
